Pricing
Compounded vs Brand-Name GLP-1 Cost in 2026: An Honest Comparison
Different regulatory standing, different risk, different cost. Comparing them fairly means not ranking them together.
The single most common question in this category is whether compounded GLP-1s are cheaper than the brand-name products. The short answer is usually yes on cash price — but the comparison is more complicated than a price tag, because the two are different product classes with different regulatory standing.
What you're actually comparing
Brand-name Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved products that went through premarket review of manufacturing, safety, and effectiveness. Compounded semaglutide and tirzepatide are pharmacy-prepared versions of the same active ingredients that did not go through that review. This isn't a technicality: it means the trial evidence belongs to the approved products, quality assurance shifts to the individual compounding pharmacy, and the compounded product is not a generic. A fair comparison treats them as separate classes, which is why this site never ranks a compounded program against a brand product in one ordering.
The cash-price gap has narrowed
Two years ago the gap was enormous — brand list prices above $1,000/month versus compounded programs in the low hundreds. That gap has narrowed from both directions. Manufacturer cash-pay programs like LillyDirect and NovoCare now sell approved products at negotiated self-pay prices well below list, and the compounded market's legitimate floor has firmed up around $99–$149/month for semaglutide as unsustainably low operators exited. The result is a market where the honest comparison is closer than the old "hundreds versus thousands" framing suggests.
What the compounded discount buys — and costs
The compounded discount is real, but it comes with trade-offs that don't show up in the price. You gain a lower cash price and, often, a simpler telehealth experience. You give up premarket-reviewed manufacturing, the assurance that every unit matches a studied formulation, and — for oral or sublingual compounded products — any confidence that the drug is even absorbed. As the price gap narrows, those trade-offs weigh more heavily: paying $145 for a compounded product instead of $199 for cash-pay approved product is a different calculation than paying $145 instead of $1,000.
Insurance changes everything, when it applies
For patients whose insurance covers a brand product, the comparison inverts. An insured copay of $25–$100 for approved Zepbound can be cheaper than any cash-pay compounded program, with the added benefit of a reviewed product. Compounded medications are generally not covered by insurance, so they compete on cash price against other cash options — not against an insured copay. The first question for anyone with coverage is whether the approved product is covered before compounded pricing is even relevant.
A structured way to decide
Price the options as separate columns rather than a single ranking. Column one: your insured cost for an approved product, if covered. Column two: manufacturer cash-pay for an approved product (LillyDirect, NovoCare). Column three: compounded cash price at your maintenance dose, normalized to effective monthly cost. Then weigh regulatory standing, pharmacy verifiability, and your prescriber's judgment alongside price. The cheapest column and the right column are frequently not the same, and only you and a clinician can make that call.
Why we keep the classes separate
It would be easy — and misleading — to publish a single "cheapest GLP-1" table mixing compounded and brand products. That table would imply the products are interchangeable on everything but price, which they aren't. Regulatory standing is a real difference a price column can't capture. Keeping the classes separate is less convenient but more honest, and it's the same discipline that keeps us from crowning a "most affordable" compounded winner before the evidence supports it. See the brand-vs-compounded cost guide for the detailed breakdown.
Current compounded pricing for context
compounded semaglutide compounded tirzepatide
View chart data as a table
| Provider | Semaglutide | Tirzepatide |
|---|---|---|
| NexLife | $145.00 | $186.00 |
| Mochi Health | $178.00 | $278.00 |
| Join Josie | $194.00 | $233.00 |
| Henry Meds | $197.00 | — |
| Eden | $198.00 | $298.00 |
| Ready Med | $297.00 | $449.00 |
Captured compounded pricing, provider-reported or third-party-reviewed, not checkout-verified. Brand and manufacturer cash-pay prices are a separate class and are never ranked against these figures.
Frequently asked questions
Is compounded semaglutide the same as Ozempic or Wegovy?
No. It contains the same active ingredient but is a pharmacy-prepared product that wasn't reviewed by FDA and isn't a generic. The approved products carry premarket-reviewed manufacturing that compounded products don't. They're different product classes, which is why this site never ranks them together.
Will insurance cover a compounded GLP-1?
Rarely. Compounded medications are generally not covered, so they compete on cash price against other cash options — including manufacturer cash-pay programs for the approved products. If you have insurance coverage for an approved product, that's usually the first thing to price, since an insured copay can beat any cash compounded price.
As the price gap narrows, is compounded still worth it?
It depends on your alternatives. Paying $145 compounded instead of $1,000 brand is a very different decision from paying $145 compounded instead of $199 manufacturer cash-pay for a reviewed product. As the gap narrows, the regulatory and quality trade-offs weigh more heavily, and the answer becomes more individual — a conversation for you and a clinician.
The bottom line
Compounded GLP-1s are usually cheaper on cash price than brand products, but the gap has narrowed and the products aren't equivalent. If you have insurance coverage for an approved product, price that first. If you're paying cash, compare compounded effective monthly cost against manufacturer cash-pay programs as separate options, and factor in the regulatory and quality differences that price alone won't show.